BSLN.SW Live signaler | Maksimer profitt med Getagraph.com

Live Chart Being Loaded With Signals

Commentary (3 mai 2024 @ 17:30):

Stats
Dagens volum	22 003.00
Gjennomsnittsvolum	36 390.00
Markedsverdi	478.93M
EPS	CHF0 ( 2024-02-13 )
Last Dividend	CHF0 ( N/A )
Next Dividend	CHF0 ( N/A )
P/E	46.40
ATR14	CHF0.109 (0.27%)

Volum Korrelasjon

Lang: -0.03 (neutral)

Kort: -0.36 (neutral)

Signal:(51.368) Neutral

Basilea Pharmaceutica AG Korrelasjon

10 Mest positive korrelasjoner

10 Mest negative korrelasjoner

Visste du det?

Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).

Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.

Basilea Pharmaceutica AG Korrelasjon - Valuta/Råvare

0.31
( neutral )

0.50
( weak )

0.00
( neutral )

-0.68
( moderate negative )

-0.59
( weak negative )

Basilea Pharmaceutica AG Økonomi

Annual	2023
Omsetning:	CHF157.63M
Bruttogevinst:	CHF130.84M (83.00 %)
EPS:	CHF0.870

FY	2023
Omsetning:	CHF157.63M
Bruttogevinst:	CHF130.84M (83.00 %)
EPS:	CHF0.870

FY	2022
Omsetning:	CHF147.77M
Bruttogevinst:	CHF120.96M (81.86 %)
EPS:	CHF1.020

FY	2021
Omsetning:	CHF148.12M
Bruttogevinst:	CHF124.05M (83.75 %)
EPS:	CHF-0.664

Financial Reports:

No articles found.

Basilea Pharmaceutica AG

Basilea Pharmaceutica AG, a commercial stage biopharmaceutical company, focuses on the development of products that address the medical needs in the therapeutic areas of oncology and anti-infectives. It offers Cresemba, an intravenous and oral azole antifungal drug for the treatment of invasive aspergillosis and mucormycosis in the United States, and the European Union, as well as in Phase III clinical trials for invasive fungal infections in Japan. The company also provides Zevtera, an antibiotic for the treatment of community and hospital-acquired pneumonia, as well as in Phase III clinical trials for the treatment of acute bacterial skin and skin structure infections, and Staphylococcus aureus bacteremia. In addition, it engages in developing Derazantinib, a small molecule inhibitor, which is in phase 2 clinical trial for bile duct cancer, as well as in phase ½ clinical trial for bladder and stomach cancer; and Lisavanbulin, a tumor checkpoint controller drug. Basilea Pharmaceutica AG was founded in 2000 and is headquartered in Basel, Switzerland.